Cu-64 Solid Target Handling System

描述（由申请人提供）：本提案的目标是获得资金，为RDS 111生物医学回旋加速器添加64 Cu靶向和处理系统，以实现放射性核素64 Cu的常规生产，用于体内分子成像研究。回旋加速器和拟议的靶向系统位于分子和基因组成像中心，这是加州大学戴维斯分校的临床前核心设施，为在动物模型中进行体内成像研究提供基础设施和专业知识。64 Cu标记的生物分子，包括64 Cu-PTSM（用于灌注和细胞标记），64 Cu标记的肽，64 Cu标记的抗体，64 Cu标记的纳米颗粒和64 Cu标记的脂质体，正在被加州大学戴维斯分校NIH资助的一大批教师用作开发新诊断和治疗药物的基础。商业来源的64 Cu每14天才交付一次，大部分放射性在运输过程中损失。因此，NIH资助的研究受到64 Cu可用性的限制。我们建议增加一个64 Cu目标和目标处理系统，这将使我们现有的RDS 111回旋加速器上的64 Cu的常规生产，提供64 Cu定期为12个NIH资助的研究人员谁利用64 Cu在他们的研究计划。 公共卫生相关性：分子成像领域寻求发现体内成像特定生物靶点和途径的新方法，最终目标是提供患者特异性和基于分子的诊断信息。此外，正在开发分子成像方法以直接监测分子靶向治疗、细胞治疗和基因治疗。使用放射性标记示踪剂的正电子发射断层扫描是分子成像的关键平台技术。放射性核素铜-64具有与许多感兴趣的生物分子的动力学相容的半衰期，因此是在该领域具有广泛应用的同位素。该提案将使加州大学戴维斯分校铜-64的常规生产能够应用于NIH资助的研究项目，这些项目涉及开发新的诊断和治疗药物，以及跟踪和可视化干细胞和祖细胞疗法。

DESCRIPTION (provided by applicant): The goal of this proposal is to secure funding to add a 64Cu targetry and handling system to a RDS 111 biomedical cyclotron to enable routine production of the radionuclide 64Cu for in vivo molecular imaging studies. The cyclotron and the proposed targetry system are housed in the Center for Molecular and Genomic Imaging, a preclinical core facility at UC Davis that provides the infrastructure and expertise to conduct in vivo imaging studies in animal models. 64Cu-labeled biomolecules, including 64Cu-PTSM (for perfusion and cell labeling), 64Cu-labeled peptides, 64Cu-labeled antibodies, 64Cu-labeled nanoparticles and 64Cu-labeled liposomes, are being used by a large group of NIH-funded faculty at UC Davis as the basis for the development of new diagnostic and therapeutic agents. Commercial sources for 64Cu only deliver once every 14 days, and large fractions of the activity are lost in transportation. Thus, NIH-funded research is limited by 64Cu availability. We propose the addition of a 64Cu target and target handling system that will enable routine production of 64Cu on our existing RDS 111 cyclotron, providing 64Cu on a regular basis for twelve NIH-funded researchers who utilize 64Cu in their research programs. PUBLIC HEALTH RELEVANCE: The field of molecular imaging seeks to discover new approaches to imaging specific biologic targets and pathways in vivo, with the ultimate goal of providing patient-specific and molecularly-based diagnostic information. In addition, molecular imaging approaches are being developed to directly monitor molecularly targeted therapies, cellular therapies and gene therapies. Positron emission tomography using radiolabeled tracers is a key platform technology for molecular imaging. The radionuclide copper-64 has a half-life compatible with the kinetics of many interesting biomolecules and is therefore an isotope with broad applications in the field. This proposal will enable routine production of copper-64 at UC Davis for application to research projects funded by NIH that involve the development of new diagnostic and therapeutic agents, and for tracking and visualization of stem and progenitor cell therapies.